Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#61
JOURNAL ARTICLE
Ghadah Al-Naqeeb, Eric Munger, Amrita L Ramanathan, Andrew Makarewicz, Noha Behairy, Padmasree Veraraghavan, Craig Cochran, Philip Bernaldez, Iman Clinton, Newbegin Devaraj, Korressa Lee, Teresa Fisher, Olumide Owoade, Roberto Maass-Moreno, Babak Saboury, Sriram Gubbi, Joanna Klubo-Gwiezdzinska
High-activity radioactive iodine (RAI) therapy for metastatic thyroid cancer (TC) requires isolation to minimize radiation exposure to third parties, thus posing challenges for patients needing hands-on care. There are limited data on the approach to high-activity RAI treatment in paraplegic patients. We report a state-of-the-art multidisciplinary approach to the management of bedbound patients, covering necessary radiation safety measures that lead to radiation exposure levels as low as reasonably achievable...
July 11, 2024: Journal of Nuclear Medicine
#62
JOURNAL ARTICLE
Julia Brosch-Lenz, Sara Kurkowska, Eric Frey, Yuni K Dewaraja, John Sunderland, Carlos Uribe
Image-based dosimetry-guided radiopharmaceutical therapy has the potential to personalize treatment by limiting toxicity to organs at risk and maximizing the therapeutic effect. The 177 Lu dosimetry challenge of the Society of Nuclear Medicine and Molecular Imaging consisted of 5 tasks assessing the variability in the dosimetry workflow. The fifth task investigated the variability associated with the last step, dose conversion, of the dosimetry workflow on which this study is based. Methods: Reference variability was assessed by 2 medical physicists using different software, methods, and all possible combinations of input segmentation formats and time points as provided in the challenge...
July 3, 2024: Journal of Nuclear Medicine
#63
JOURNAL ARTICLE
Christoph Oster, Lukas Kessler, Tobias Blau, Kathy Keyvani, Kim M Pabst, Wolfgang P Fendler, Pedro Fragoso Costa, Lazaros Lazaridis, Teresa Schmidt, Jonas Feldheim, Daniela Pierscianek, Hans Ulrich Schildhaus, Ulrich Sure, Yahya Ahmadipour, Christoph Kleinschnitz, Nika Guberina, Martin Stuschke, Cornelius Deuschl, Björn Scheffler, Ken Herrmann, Sied Kebir, Martin Glas
Despite their unique histologic features, gliosarcomas belong to the group of glioblastomas and are treated according to the same standards. Fibroblast activation protein (FAP) is a component of a tumor-specific subpopulation of fibroblasts that plays a critical role in tumor growth and invasion. Some case studies suggest an elevated expression of FAP in glioblastoma and a particularly strong expression in gliosarcoma attributed to traits of predominant mesenchymal differentiation. However, the prognostic impact of FAP and its diagnostic and therapeutic potential remain unclear...
July 3, 2024: Journal of Nuclear Medicine
#64
JOURNAL ARTICLE
Zachary Ells, Tristan R Grogan, Johannes Czernin, Magnus Dahlbom, Jeremie Calais
Novel theranostic approaches using radiopharmaceuticals targeting prostate-specific membrane antigen (PSMA) have emerged for treating metastatic castration-resistant prostate cancer. The physical properties and commercial availability of 177 Lu make it one of the most used radionuclides for radiopharmaceutical therapy (RPT). In this literature review, we aimed at comparing the dosimetry of the most used [177 Lu]Lu-PSMA RPT compounds. Methods: This was a systematic review and metaanalysis of [177 Lu]Lu-PSMA RPT (617, I&T, and J591) dosimetry in patients with prostate cancer...
July 3, 2024: Journal of Nuclear Medicine
#65
JOURNAL ARTICLE
Zhonglin Lu, Daniel F Polan, Lise Wei, Madhava P Aryal, Kellen Fitzpatrick, Chang Wang, Kyle C Cuneo, Joseph R Evans, Molly E Roseland, Joseph J Gemmete, Jared A Christensen, Baljendra S Kapoor, Justin K Mikell, Yue Cao, Greta S P Mok, Yuni K Dewaraja
Functional liver parenchyma can be damaged from treatment of liver malignancies with 90 Y selective internal radiation therapy (SIRT). Evaluating functional parenchymal changes and developing an absorbed dose (AD)-toxicity model can assist the clinical management of patients receiving SIRT. We aimed to determine whether there is a correlation between 90 Y PET AD voxel maps and spatial changes in the nontumoral liver (NTL) function derived from dynamic gadoxetic acid-enhanced MRI before and after SIRT. Methods: Dynamic gadoxetic acid-enhanced MRI scans were acquired before and after treatment for 11 patients undergoing 90 Y SIRT...
July 3, 2024: Journal of Nuclear Medicine
#66
JOURNAL ARTICLE
Sandra Resch, Sibylle I Ziegler, Gabriel Sheikh, Lena M Unterrainer, Mathias J Zacherl, Peter Bartenstein, Guido Böning, Julia Brosch-Lenz, Astrid Delker
Internal dosimetry supports safe and effective patient management during radionuclide therapy. Yet, it is associated with high clinical workload, costs, and patient burden, as patient scans at multiple time points (MTPs) must be acquired. Dosimetry based on imaging at a single time point (STP) has continuously gained popularity. However, MTP protocols, used as a reference to judge the validity of STP dosimetry, differ depending on local requirements and deviate from the unknown patient-specific ground truth pharmacokinetics...
June 27, 2024: Journal of Nuclear Medicine
#67
JOURNAL ARTICLE
Duminduni Hewa Angappulige, Nimrod S Barashi, Nicholas Pickersgill, Cody Weimholt, Jingqin Luo, Ghazal Shadmani, Ziad Tarcha, Sampanna Rayamajhi, Nupam P Mahajan, Gerald L Andriole, Barry A Siegel, Eric H Kim, Kiran Mahajan
Homeobox 13 (HOXB13) is an oncogenic transcription factor that directly regulates expression of folate hydrolase 1, which encodes prostate-specific membrane antigen (PSMA). HOXB13 is expressed in primary and metastatic prostate cancers (PCs) and promotes androgen-independent PC growth. Since HOXB13 promotes resistance to androgen receptor (AR)-targeted therapies and regulates the expression of folate hydrolase 1, we investigated whether SUVs on PSMA PET would correlate with HOXB13 expression. Methods: We analyzed 2 independent PC patient cohorts who underwent PSMA PET/CT for initial staging or for biochemical recurrence...
June 27, 2024: Journal of Nuclear Medicine
#68
JOURNAL ARTICLE
Virginie Combet-Curt, Chloé Buchalet, Karine Le Malicot, Claire Lemanski, Emmanuel Deshayes, Nathalie Bonichon-Lamichhane, Astrid Lièvre, Florence Huguet, Ghoufrane Tlili, Véronique Vendrely
This study aimed to evaluate the prognostic value of 18 F-FDG PET/CT qualitative assessment in terms of recurrence-free survival (RFS), colostomy-free survival (CFS), and overall survival (OS) after radiation therapy (RT) of squamous cell carcinoma of the anus (SCCA). Secondary objectives were to evaluate the prognostic value of baseline and posttherapeutic quantitative 18 F-FDG PET/CT parameters in terms of RFS, CFS, and OS. Methods: We included all consecutive patients from the French multicentric cohort FFCD-ANABASE who had undergone 18 F-FDG PET/CT at baseline and 4-6 mo after RT or chemoradiotherapy for a localized SCCA...
June 27, 2024: Journal of Nuclear Medicine
#69
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
September 3, 2024: Journal of Nuclear Medicine
#70
JOURNAL ARTICLE
James P Buteau, Louise Kostos, Ramin Alipour, Price Jackson, Lachlan McInstosh, Brittany Emmerson, Mohammad B Haskali, Jing Xie, Elizabeth Medhurst, Rajeev Ravi, Brian D Gonzalez, Heidi Fettke, Benjamin Blyth, Luc Furic, Katie Owen, Shahneen Sandhu, Declan G Murphy, Arun A Azad, Michael S Hofman
[177 Lu]Lu-PSMA is an effective class of therapy for patients with metastatic castration-resistant prostate cancer (mCRPC); however, progression is inevitable. The limited durability of response may be partially explained by the presence of micrometastatic deposits, which are energy-sheltered and receive low absorbed radiation with 177 Lu due to the approximately 0.7-mm mean pathlength. 161 Tb has abundant emission of Auger and conversion electrons that deposit a higher concentration of radiation over a shorter path, particularly to single tumor cells and micrometastases...
August 1, 2024: Journal of Nuclear Medicine
#71
JOURNAL ARTICLE
Lisa Steinhelfer, Friederike Jungmann, Lukas Endrös, Patrick Wenzel, Bernhard Haller, Manuel Nickel, Eva Haneder, Fabian Geisler, Katharina Götze, Alexander von Werder, Matthias Eiber, Markus R Makowski, Rickmer Braren, Fabian Lohöfer
177 Lu-DOTATATE therapy is an effective treatment for advanced neuroendocrine tumors, despite its dose-limiting hematotoxicity. Herein, the significance of off-target splenic irradiation is unknown. Our study aims to identify predictive markers of peptide receptor radionuclide therapy-induced leukopenia. Methods: We retrospectively analyzed blood counts and imaging data of 88 patients with histologically confirmed, unresectable metastatic neuroendocrine tumors who received 177 Lu-DOTATATE treatment at our institution from February 2009 to July 2021...
August 1, 2024: Journal of Nuclear Medicine
#72
COMPARATIVE STUDY
Lukas Kessler, Felix Schwaning, Martin Metzenmacher, Kim Pabst, Jens Siveke, Marija Trajkovic-Arsic, Benedikt Schaarschmidt, Marcel Wiesweg, Clemens Aigner, Till Plönes, Kaid Darwiche, Servet Bölükbas, Martin Stuschke, Lale Umutlu, Michael Nader, Dirk Theegarten, Rainer Hamacher, Wilfried E E Eberhardt, Martin Schuler, Ken Herrmann, Wolfgang P Fendler, Hubertus Hautzel
The fibroblast activation protein (FAP) is highly expressed in tumor and stromal cells of mesothelioma and thus is an interesting imaging and therapeutic target. Previous data on PET imaging with radiolabeled FAP inhibitors (FAPIs) suggest high potential for superior tumor detection. Here, we report the data of a large malignant pleural mesothelioma cohort within a 68 Ga-FAPI46 PET observational trial (NCT04571086). Methods: Of 43 eligible patients with suspected or proven malignant mesothelioma, 41 could be included in the data analysis of the 68 Ga-FAPI46 PET observational trial...
August 1, 2024: Journal of Nuclear Medicine
#73
JOURNAL ARTICLE
Lise Borgwardt, Jesper Brok, Kim Francis Andersen, Jacob Madsen, Nicholas Gillings, Marie Øbro Fosbøl, Charlotte Lund Denholt, Ida Nymann Petersen, Louise Sørup Sørensen, Lotte Hahn Enevoldsen, Peter Sandor Oturai, Helle Hjort Johannesen, Liselotte Højgaard, Christina Schulze, Eunice Saxtoft, Flemming Andersen, Barbara Malene Fischer
Meta-[123 I]iodobenzylguanidine ([123 I]MIBG) scintigraphy with SPECT/CT is the standard of care for diagnosing and monitoring neuroblastoma. Replacing [123 I]MIBG with the new PET tracer meta-[18 F]fluorobenzylguanidine ([18 F]MFBG) and further improving sensitivity and reducing noise in a new long-axial-field-of-view (LAFOV) PET/CT scanner enable increased image quality and a faster acquisition time, allowing examinations to be performed without sedation or general anesthesia (GA). Focusing on feasibility, we present our first experience with [18 F]MFBG LAFOV PET/CT and compare it with [123 I]MIBG scintigraphy plus SPECT/CT for imaging in neuroblastoma in children...
August 1, 2024: Journal of Nuclear Medicine
#74
JOURNAL ARTICLE
Dauren Adilbay, Junior Gonzales, Marianna Zazhytska, Paula Demetrio de Souza Franca, Sheryl Roberts, Tara D Viray, Raik Artschwager, Snehal Patel, Albana Kodra, Jonathan B Overdevest, Chun Yuen Chow, Glenn F King, Sanjay K Jain, Alvaro A Ordonez, Laurence S Carroll, Stavros Lomvardas, Thomas Reiner, Nagavarakishore Pillarsetty
Despite the recent advances in understanding the mechanisms of olfaction, no tools are currently available to noninvasively identify loss of smell. Because of the substantial increase in patients presenting with coronavirus disease 2019-related loss of smell, the pandemic has highlighted the urgent need to develop quantitative methods. Methods: Our group investigated the use of a novel fluorescent probe named Tsp1a-IR800P as a tool to diagnose loss of smell. Tsp1a-IR800P targets sodium channel 1.7, which plays a critical role in olfaction by aiding the signal propagation to the olfactory bulb...
August 1, 2024: Journal of Nuclear Medicine
#75
JOURNAL ARTICLE
Esther M M Smeets, Marija Trajkovic-Arsic, Daan Geijs, Sinan Karakaya, Monica van Zanten, Lodewijk A A Brosens, Benedikt Feuerecker, Martin Gotthardt, Jens T Siveke, Rickmer Braren, Francesco Ciompi, Erik H J G Aarntzen
Radiomics features can reveal hidden patterns in a tumor but usually lack an underlying biologic rationale. In this work, we aimed to investigate whether there is a correlation between radiomics features extracted from [18 F]FDG PET images and histologic expression patterns of a glycolytic marker, monocarboxylate transporter-4 (MCT4), in pancreatic cancer. Methods: A cohort of pancreatic ductal adenocarcinoma patients ( n = 29) for whom both tumor cross sections and [18 F]FDG PET/CT scans were available was used to develop an [18 F]FDG PET radiomics signature...
July 1, 2024: Journal of Nuclear Medicine
#76
JOURNAL ARTICLE
Moe S Sadaghiani, Saradha Baskaran, Michael A Gorin, Steven P Rowe, Jean-Claude Provost, Iryna Teslenko, Roman Bilyk, Hong An, Sara Sheikhbahaei
Prostate-specific membrane antigen (PSMA) is expressed in the neovasculature of multiple solid tumors, including renal cell carcinoma (RCC). Studies have demonstrated promising results on the utility of PSMA-targeted PET/CT imaging in RCC. This report aims to provide a systematic review and metaanalysis on the utility and detection rate of PSMA PET/CT imaging in staging or evaluation of primary RCC and restaging of metastatic or recurrent RCC. Methods: Searches were performed in PubMed, Embase, and abstract proceedings (last updated, August 2023)...
July 1, 2024: Journal of Nuclear Medicine
#77
MULTICENTER STUDY
Roel Hoek, Pepijn A van Diemen, Pieter G Raijmakers, Roel S Driessen, Yvemarie B O Somsen, Ruben W de Winter, Ruurt A Jukema, Jos W R Twisk, Lourens F H J Robbers, Pim van der Harst, Antti Saraste, Mark Lubberink, Jens Sörensen, Paul Knaapen, Juhani Knuuti, Ibrahim Danad
Currently, cutoffs of quantitative [15 O]H2 O PET to detect fractional flow reserve (FFR)-defined coronary artery disease (CAD) were derived from a single cohort that included patients without prior CAD. However, prior CAD, sex, and age can influence myocardial blood flow (MBF). Therefore, the present study determined the influence of prior CAD, sex, and age on optimal cutoffs of hyperemic MBF (hMBF) and coronary flow reserve (CFR) and evaluated whether cutoff optimization enhanced diagnostic performance of quantitative [15 O]H2 O PET against an FFR reference standard...
July 1, 2024: Journal of Nuclear Medicine
#78
LETTER
Isabelle Laverdière, Gilbert Matte, Martin Darveau, Jean-Mathieu Beauregard
No abstract text is available yet for this article.
June 21, 2024: Journal of Nuclear Medicine
#79
JOURNAL ARTICLE
Mohan Doss
The linear no-threshold (LNT) model, which asserts that any level of ionizing radiation increases cancer risk, has been the basis of global radiation protection policies since the 1950s. Despite ongoing endorsements, a growing body of evidence challenges the LNT model, suggesting instead that low-level radiation exposure might reduce cancer risk, a concept known as radiation hormesis. This editorial examines the persistence of the LNT model despite evidence favoring radiation hormesis and proposes a solution: a public, online debate between proponents of the LNT model and advocates of radiation hormesis...
June 21, 2024: Journal of Nuclear Medicine
#80
JOURNAL ARTICLE
Matteo Bauckneht, Francesco Lanfranchi, Domenico Albano, Luca Triggiani, Flavia Linguanti, Luca Urso, Rosario Mazzola, Alessio Rizzo, Elisa D'Angelo, Francesco Dondi, Eneida Mataj, Gloria Pedersoli, Elisabetta Maria Abenavoli, Luca Vaggelli, Beatrice Detti, Naima Ortolan, Antonio Malorgio, Alessia Guarneri, Federico Garrou, Matilde Fiorini, Serena Grimaldi, Pietro Ghedini, Giuseppe Carlo Iorio, Antonella Iudicello, Guido Rovera, Giuseppe Fornarini, Diego Bongiovanni, Michela Marcenaro, Filippo Maria Pazienza, Giorgia Timon, Matteo Salgarello, Manuela Racca, Mirco Bartolomei, Stefano Panareo, Umberto Ricardi, Francesco Bertagna, Filippo Alongi, Salvina Barra, Silvia Morbelli, Gianmario Sambuceti, Liliana Belgioia
Metastasis-directed therapy (MDT) has been tested in clinical trials as a treatment option for oligorecurrent prostate cancer (PCa). However, there is an ongoing debate regarding the impact of using different imaging techniques interchangeably for defining lesions and guiding MDT within clinical trials. Methods: We retrospectively identified oligorecurrent PCa patients who had 5 or fewer nodal, bone, or visceral metastases detected by choline or prostate-specific membrane antigen (PSMA) PET/CT and who underwent MDT stereotactic body radiotherapy with or without systemic therapy in 8 tertiary-level cancer centers...
June 21, 2024: Journal of Nuclear Medicine
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
